{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:29Z","timestamp":1791232469113,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1608,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1600-0609.2011.01598.x","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T00:48:47Z","timestamp":1299026927000},"page":"531-535","source":"Crossref","is-referenced-by-count":48,"title":["A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib"],"prefix":"10.1111","volume":"86","author":[{"given":"Andrzej","family":"Mital","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Piskorz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Was\u0105g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Limon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,7]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0889-8588(05)70299-9","article-title":"Pediatric mastocytosis","volume":"14","author":"Hartmann","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"E1906","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.beha.2005.07.010","article-title":"Pathogenesis, clinical features, and treatment advances in mastocytosis","volume":"19","author":"Pardanani","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3324\/haematol.11558","article-title":"Biochemical markers predictive for bon marrow involvement in systemic mastocytosis","volume":"93","author":"Donker","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.5858\/2007-131-784-SMACCA","article-title":"Systemic mastocytosis: a concise clinical and laboratory review","volume":"131","author":"Patnaik","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB8|cit8","first-page":"54","volume-title":"WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues","author":"Horny","year":"2008"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB11|cit11","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel 5090 mutation of KIT identified in familial mastocytosis: in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-07-4575","article-title":"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases","volume":"14","author":"Heinrich","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2559.2008.02977.x","article-title":"Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumors","volume":"53","author":"Lasota","year":"2008","journal-title":"Histopathology"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon \u03b1-2b and prednisolone in aggressive systemic masocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB21|cit21","first-page":"393","article-title":"Cladribine therapy for systemic mastocytosis","volume":"36","author":"Kluin-Nelemans","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3324\/haematol.12324","article-title":"How we diagnose and treat WHO-defined systemic mastocytosis in adults","volume":"3","author":"Tefferi","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1600-0609.2011.01598.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection of imatinib in patients with advanced gastrointestinal stromal tumors","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01598.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01598.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T17:21:23Z","timestamp":1637342483000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01598.x"}},"subtitle":["Mast cell leukemia with KIT mutation"],"short-title":[],"issued":{"date-parts":[[2011,4,7]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01598.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,7]]}}}